The first vaccine in the world to prevent lung cancer develop British scientists

A particularly important news about him comes from Britain, where scientists develop the first in the world to prevent the disease in people at high risk. Scientists from the Francis Crick Institute, University College of London and Oxford University created the “LungVax”, a vaccine that activates the immune system to kill cancer cells and stop lung cancer. The vaccine was created using technology similar to the Oxford-AstraZeneca Covid-19 vaccine, reports Sky News. The group has received up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation to produce 3,000 doses of the vaccine. The vaccine uses a DNA clone that “trains” the immune system to recognize any “red flag” proteins in lung cancer cells, known as neoantigens, and kill them. Neoantigens appear on the cell surface due to mutations in the cell DNA. There are approximately 48,500 cases of lung cancer in the UK every year according to Cancer Research UK. About 72% of cases are caused by smoking. LungVax provides a “really important step where cancer can be prevented most, Cancer Research UK director Michelle Mitchell said. “The science that successfully led the world out of the pandemic could soon guide us to a future where people can live longer, better lives free from the fear of cancer,” he said. “We are in a golden age of research and this is one of many projects we hope to transform the survival of lung cancer”. The vaccine will pass a clinical trial if it shows successfully that it activates an immune response to a laboratory environment. Positive results could lead to greater tests for high risk people for the disease, including smokers aged 55 to 74 years. Professor Mariam Jamal-Hanjani, who will lead the test, said: “less than 10% of people with lung cancer survive their disease for 10 years or longer. This has to change. “This research complements existing efforts through lung health checks to early detect lung cancer in people at greater risk”. He added that based on early predictions the vaccine has the potential to cover about 90% of all lung cancers. He also noted: “LungVax will not replace smoking cessation as the best way to reduce lung cancer risk”. However, the vaccine could offer a sustainable way to prevent the occurrence of some of the cancers at an early stage.